Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Summary

The primary purpose of this study is to identify an appropriate dose of study medication.

Timeline

Start

2012-06

Primary completion

2013-06

Completion

2015-06

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo + Methotrexate (MTX) vs Clazakizumab (5 mg) + MTX; p <0.001; Mixed Models Analysis NCT02015520 ↗

registry analysis (superiority test); Placebo + Methotrexate (MTX) vs Clazakizumab (25 mg) + MTX; p <0.001; Mixed Models Analysis NCT02015520 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clazakizumab	Monoclonal antibody	—	Subcutaneous

Indications